verapamil 120mg tablet + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type1 Diabetes
Conditions
Type1 Diabetes
Trial Timeline
Jul 9, 2020 → Sep 30, 2022
NCT ID
NCT04233034About verapamil 120mg tablet + placebo
verapamil 120mg tablet + placebo is a phase 3 stage product being developed by Dexcom for Type1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT04233034. Target conditions include Type1 Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04233034 | Phase 3 | Completed |
Competing Products
11 competing products in Type1 Diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose | Precigen | Phase 1/2 | 36 |
| Insulin Lispro | Eli Lilly | Phase 1 | 33 |
| LY900014 + Insulin Lispro | Eli Lilly | Phase 2 | 52 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Dapagliflozin + Placebo Oral Tablet | AstraZeneca | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| Aspart | Novo Nordisk | Approved | 84 |
| Insulin glargine new formulation HOE901 | Sanofi | Phase 1 | 32 |
| Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin | Sanofi | Phase 1 | 32 |
| UP421 | Sana Biotechnology | Phase 1 | 28 |
| XeriSol glucagon | Xeris Pharmaceuticals | Phase 1 | 28 |